Pancreatic cancer — frontier options in Missouri

Prefer to look first? Browse the live map without signing up.

30 open options

TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2B694 · A2B543 · xT CDx with HLA-LOH Assay — 12 sites
TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 223 sites
TRIALPHASE2RECRUITING
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Stereotactic body radiotherapy · Defactinib · Avutometinib — 1 site
TRIALPHASE2 / PHASE3RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib · Everolimus — 126 sites
TRIALNARECRUITING
The Vanguard Study: Testing a New Way to Screen for Cancer
Biospecimen Collection · Device Usage · Electronic Health Record Review — 44 sites
TRIALPHASE2 / PHASE3RECRUITING
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Telisotuzumab adizutecan · Fluorouracil · Folinic acid/ Leucovorina — 19 sites
TRIALNARECRUITING
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
Next Generation Delivery System (NGDS) — 2 sites
TRIALPHASE1 / PHASE2RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Biospecimen Collection · Dual X-ray Absorptiometry · Tegavivint — 21 sites
TRIALPHASE1RECRUITING
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA-313 · Olaparib — 18 sites
TRIALPHASE1RECRUITING
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 — 7 sites
TRIALPHASE1RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Darlifarnib · Cabozantinib · Adagrasib — 38 sites
TRIALPHASE2RECRUITING
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
nuzefatide pevedotin (BT5528) — 8 sites
TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
TRIALPHASE3RECRUITING
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Biospecimen Collection · Distal Pancreatectomy · Lanreotide — 118 sites
TRIALPHASE1RECRUITING
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Biopsy Procedure · Biospecimen Collection · Computed Tomography — 18 sites
TRIALPHASE1RECRUITING
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
XL309 · Olaparib — 16 sites
TRIALPHASE1RECRUITING
IDOV-Immune for Advanced Solid Tumors
IDOV-Immune (oncolytic vaccinia virus) — 5 sites
TRIALPHASE1RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
LY4337713 — 30 sites
TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 78 sites
TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab — 14 sites
TRIALPHASE2RECRUITING
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
VS-7375 · cetuximab — 29 sites
TRIALPHASE1 / PHASE2RECRUITING
Lead-212 PSV359 Therapy for Patients With Solid Tumors
[203Pb]Pb-PSV359 · [212Pb]Pb-PSV359 — 11 sites
TRIALPHASE3RECRUITING
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Biospecimen Collection · Computed Tomography · Fluorouracil — 274 sites
TRIALPHASE1 / PHASE2RECRUITING
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
JAB-23E73 · JAB-23E73 · JAB-23E73 — 4 sites
TRIALPHASE2RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
HER3-DXd — 91 sites
TRIALPHASE1 / PHASE2RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ART0380 · Gemcitabine · Irinotecan — 82 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.